Skip Nav Destination
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Factor VIII gene variants and inhibitor risk in African American hemophilia A patients
Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury
Issue Archive
Table of Contents
INSIDE BLOOD COMMENTARIES
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Clinical Trials & Observations
Samantha M. Jaglowski,Jeffrey A. Jones,Veena Nagar,Joseph M. Flynn,Leslie A. Andritsos,Kami J. Maddocks,Jennifer A. Woyach,Kristie A. Blum,Michael R. Grever,Kelly Smucker,Amy S. Ruppert,Nyla A. Heerema,Gerard Lozanski,Mona Stefanos,Brian Munneke,Jamie-Sue West,Jutta K. Neuenburg,Danelle F. James,Nathan Hall,Amy J. Johnson,John C. Byrd
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Clinical Trials & Observations
Brief Report
Joaquín Martínez-López,Bruno Paiva,Lucía López-Anglada,María-Victoria Mateos,Teresa Cedena,María-Belén Vidríales,María Auxiliadora Sáez-Gómez,Teresa Contreras,Albert Oriol,Inmaculada Rapado,Ana-Isabel Teruel,Lourdes Cordón,María Jesús Blanchard,Enrique Bengoechea,Luis Palomera,Felipe de Arriba,Cecilia Cueto-Felgueroso,Alberto Orfao,Joan Bladé,Jesús F. San Miguel,Juan José Lahuerta,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group
LYMPHOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Factor VIII gene variants and inhibitor risk in African American hemophilia A patients
Clinical Trials & Observations
Devi Gunasekera,Ruth A. Ettinger,Shelley Nakaya Fletcher,Eddie A. James,Maochang Liu,John C. Barrett,Janice Withycombe,Dana C. Matthews,Melinda S. Epstein,Richard J. Hughes,Kathleen P. Pratt,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators
Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury
Brief Report
Eimear M. Gleeson,María G. Dichiara,Agustina Salicio,Louise M. Quinn,Clive Drakeford,Shane E. Russell,Patrick T. Walsh,Josune Orbe,José Hermida,Owen P. Smith,James S. O’Donnell,Ramón Montes,Roger J. S. Preston
BLOOD WORK
CORRESPONDENCE
-
Cover Image
Cover Image
![issue cover]()
This case of Epstein-Barr virus–positive diffuse large B-cell lymphoma arose in a 27-year-old pregnant female. The neoplastic large lymphoid cells dissected through the skeletal muscle fibers of the chest wall (original magnification ×200; hematoxylin and eosin stain). Separately, the neoplastic cells were positive for CD79a, PAX5, MUM1, LMP1, and EBNA2 in Figure 3 (see the article by Nicolae et al on page 863).
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
